J.P. Morgan Chase put an end to the uncertainty surrounding its annual health care conference, announcing that the 40th edition will move to a virtual format.
Biogen announced plans to present data on the company’s portfolio, including the controversial medicine Aduhelm (aducanumab), at the annual Clinical Trials on Alzheimer’s Disease conference (CTAD) scheduled for November 9-12.
Biogen Inc. and partner Eisai Co. Ltd. on July 29 revealed the design of an upcoming study of their controversial Alzheimer’s treatment, Aduhelm.
One of the eagerly anticipated presentations at the 2021 Alzheimer’s Association International Conference in Denver and virtually is Biogen and the company’s partner Eisai on their controversial drug Aduhelm (aducanumab). Biogen is also presenting new data on a different Alzheimer’s drug with another partner, Ionis Pharmaceuticals.
BioSpace takes a look at some of the stories from the first day of the Alzheimer’s Association International Conference 2021 (AAIC).
As the 2021 virtual J.P. Morgan Healthcare Conference wrapped up, BioSpace reviewed news from companies regarding their deals, pipeline and regulatory updates.
BioSpace looks at some of the top stories from Day 2 of the virtual JP Morgan Annual Healthcare Conference.
At the 2021 virtual JP Morgan Healthcare Conference, Vertex Pharmaceuticals’ chief executive officer Reshma Kewalramani said the company is looking to buy “mid- and late-stage assets.”
Immunity from Moderna Inc.’s Covid-19 vaccine should last at least a year, the company said at the J.P. Morgan Healthcare conference.
Initially traced to about 100 cases of Covid-19 that spread across the United States, the number of infections linked to a Biogen corporate conference held in February 2020 at the Boston Marriott Long Wharf Hotel has grown exponentially and researchers estimate the total could be as many as 300,000.
